XOMA Royalty Declares Quarterly Preferred Stock Dividends
- Regular dividend payments demonstrate financial stability and commitment to preferred shareholders
- Maintained consistent dividend rates for both preferred stock series
- None.
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:
Holders of the
Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s
The preferred dividends will be paid on or about July 15, 2025, to respective holders of record at the close of business on July 3, 2025.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel
Investor contact: | Media contact: |
Juliane Snowden | Kathy Vincent |
XOMA Royalty Corporation | KV Consulting & Management |
+1-646-438-9754 | +1-310-403-8951 |
juliane.snowden@xoma.com | kathy@kathyvincent.com |
